3675 Market Street
Suite 200
Philadelphia, PA 19104
United States
267-491-6422
https://carismatx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Steven Kelly | President, CEO & Director | 666k | N/D | 1965 |
Mr. Michael Klichinsky Ph.D., Pharm.D., PharmD | Co-Founder & Chief Scientific Officer | 469k | N/D | 1990 |
Mr. Richard S. Morris CPA | CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off. | 570k | N/D | 1974 |
Mr. Saar Gill M.D., Ph.D. | Co-Founder | N/D | N/D | N/D |
Dr. Daniel J. Cushing FCP, Ph.D. | Chief Technology & Development Officer | N/D | N/D | N/D |
Mr. Eric H. Siegel J.D., MBA | General Counsel & Corporate Secretary | N/D | N/D | 1965 |
Ms. Terry Shields | Senior Vice President of Human Resources | N/D | N/D | N/D |
Mr. Tom Wilton | Chief Business Officer | N/D | N/D | 1974 |
Carisma Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
L'ISS Governance QualityScore di Carisma Therapeutics, Inc. al 1 marzo 2024 è 7. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 6; diritti degli azionisti: 7; retribuzione: 8.